WO2001037780A8 - Urotensin-ii analogs - Google Patents

Urotensin-ii analogs

Info

Publication number
WO2001037780A8
WO2001037780A8 PCT/US2000/032408 US0032408W WO0137780A8 WO 2001037780 A8 WO2001037780 A8 WO 2001037780A8 US 0032408 W US0032408 W US 0032408W WO 0137780 A8 WO0137780 A8 WO 0137780A8
Authority
WO
WIPO (PCT)
Prior art keywords
urotensin
analogs
cyclic
general
pharmaceutical compositions
Prior art date
Application number
PCT/US2000/032408
Other languages
French (fr)
Other versions
WO2001037780A2 (en
Inventor
Dashyant Dhanak
Steven D Knight
Gregory L Warren
Original Assignee
Smithkline Beecham Corp
Dashyant Dhanak
Steven D Knight
Gregory L Warren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Dashyant Dhanak, Steven D Knight, Gregory L Warren filed Critical Smithkline Beecham Corp
Priority to JP2001539397A priority Critical patent/JP2003527341A/en
Priority to EP00980842A priority patent/EP1233774A4/en
Publication of WO2001037780A2 publication Critical patent/WO2001037780A2/en
Publication of WO2001037780A8 publication Critical patent/WO2001037780A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

La présente invention concerne, d'une manière générale, les analogues d'urotensine II cyclique et les compositions pharmaceutiques les renfermant.The present invention relates, in general, to cyclic urotensin II analogs and to the pharmaceutical compositions containing them.

PCT/US2000/032408 1999-11-29 2000-11-29 Urotensin-ii analogs WO2001037780A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2001539397A JP2003527341A (en) 1999-11-29 2000-11-29 Urotensin-II analog
EP00980842A EP1233774A4 (en) 1999-11-29 2000-11-29 Urotensin-ii analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16814199P 1999-11-29 1999-11-29
US60/168,141 1999-11-29

Publications (2)

Publication Number Publication Date
WO2001037780A2 WO2001037780A2 (en) 2001-05-31
WO2001037780A8 true WO2001037780A8 (en) 2001-11-08

Family

ID=22610297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/032408 WO2001037780A2 (en) 1999-11-29 2000-11-29 Urotensin-ii analogs

Country Status (3)

Country Link
EP (1) EP1233774A4 (en)
JP (1) JP2003527341A (en)
WO (1) WO2001037780A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355940B1 (en) * 2000-10-20 2007-10-03 The Administrators of The Tulane Educational Fund Urotensin-ii agonists and antagonists
AU2003275602A1 (en) * 2002-10-25 2004-05-13 Takeda Pharmaceutical Company Limited Antibody and utilization of the same
ITFI20030238A1 (en) 2003-09-11 2005-03-12 Paolo Grieco UROTENSIN ANTAGONIST CYCLIC PEPTIDES-II
ITFI20070032A1 (en) * 2007-02-09 2008-08-10 Alfredo Budillon LIGANDS OF PEPTIDIC AND NON-PEPTIDIC NATURE OF THE UT RECEIVER OF UROTENSIN-II, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE.
JP2014518854A (en) 2011-05-03 2014-08-07 アンスティテュート・ナショナル・ドゥ・ラ・ルシェルシェ・サイエンティフィーク Novel agonists and antagonists of urotensin agonist system
FR2982488B1 (en) * 2011-11-10 2013-12-27 Univ Rouen UROTENSIN II FOR USE IN THE TREATMENT AND / OR PREVENTION OF PATHOLOGIES INVOLVING GASTRIC MOTILITY

Also Published As

Publication number Publication date
EP1233774A4 (en) 2004-06-16
JP2003527341A (en) 2003-09-16
WO2001037780A2 (en) 2001-05-31
EP1233774A1 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
DK1091975T3 (en) New cyclosporine with improved activity profile
HK1028548A1 (en) Formulations for hydrophobic pharmaceutical agents
EA200100519A1 (en) COMPOSITIONS ON THE BASIS OF A FINE-GROUNDED EPLERENON
PT1157037E (en) GCSF CONJUGATES
ATE429210T1 (en) ORAL LIQUID COMPOSITIONS
BR9810495A (en) Pharmaceutical composition
EA199900373A2 (en) PHARMACEUTICAL COMPOSITIONS
ATE383169T1 (en) COMPONENT AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
SE9802729D0 (en) Novel Compounds
EA200000548A1 (en) SPHEROIDS, METHOD FOR PRODUCING AND PHARMACEUTICAL COMPOSITIONS
BG103930A (en) Eletriptan hemisulphate and caffeine containing pharmaceutical compositions
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
DE69836678D1 (en) CHINOLIN AND CHINAZOLINE DERIVATIVES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF)
PT1032391E (en) PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS
WO2001037780A8 (en) Urotensin-ii analogs
DK1092431T3 (en) Lasofoxifene preparations
DE69921486D1 (en) DEXTRAN-LEPTIN CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
ATE245028T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING TRIMEGESTONE
BR9714279A (en) Aqueous preparation, and, use of it.
TR200002293T2 (en) Pharmaceutical compositions.
DK0977871T3 (en) Neurotrypsin
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
MXPA02012015A (en) Ligands of integrin receptors.
DE69900466D1 (en) ORAL COMPOSITIONS WITH LOW-DOSED CYTOTOXIC PROTEINS
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

D17 Declaration under article 17(2)a
WWE Wipo information: entry into national phase

Ref document number: 2000980842

Country of ref document: EP

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 539397

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000980842

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000980842

Country of ref document: EP